Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Indeed, I've dipped in and out of here and made some decent profits in the past, but perhaps sold a bit early last time rather than wait for it to reach £8+ back in mid 2014. However this time I do intend to wait for it to get there.
Yep, you've got off to a good start --- Hope it continues for you but it has just bounced from very oversold and may well continue now up to the three month downtrend around the 595p level , so that's another 20p --- a healthy 8% , which ain't bad in a few days. After that comes the big test ( technically at least ) at the 600p marker --- GL tho' as i bought a few at 555p after reading your post the other day --- you've been a long term admirer of this one , if memory serves .
The initial mark up at opening and then the steady strength yesterday led me to believe that this had definitely bottomed on Thursday at £5.51 so I finally ditched some banking shares that were both up over 40% in just over 3 months to join the Party here. I'd be more than happy to see a similar return in say the next 6 months.
Looks like things might be taking off so joined the party to-day. Share prices seem so high at present and it's hard to find a bargain
Just waiting for this to bottom before having a punt. The question is, where is the bottom. Brokers still have a target price of £8+ so even if I don't judge the bottom correctly, in the longer term it should still be a decent investment.
I think it is time for a new CEO etc, they all seem to have switched off with regards to the share price after landing nice fat bonuses (but why after the share price performance this last 18 months)
When is this going to hit the bottom drip drip drip drop
Take over would be nice
Well, it certainly looks like Louise and Rolf know the right time to sell their share options dunnit eh? Quiet 'ere innit?
CEO Summary Louise Makin, BTG's CEO, commented: "The business has performed well during the first half, and the outlook for the full year is strong. We have the capabilities and financial strength to take advantage of the increasing opportunities we are seeing to expand our Interventional Medicine business. By accelerating our growth strategy through reinvestment of our cash flows to maximise the value of and expand the current portfolio, we can build leadership positions in selected areas of interventional medicine and thereby create sustainable value for shareholders." Outlook BTG has performed well in the first half, with double-digit revenue growth, strong free cash flow and disciplined cost control. Through the acquisition of Galil Medical we have strengthened our portfolio, capabilities and leadership in Interventional Medicine, which is our fastest growing and highest revenue business. We have the resources and capabilities to capitalise on the expanding opportunities we see in Interventional Medicine, by reinvesting our strong cash flows into further commercial expansion, pipeline development and acquisitions. In this way we will deliver double-digit compound annual revenue growth, cement our leadership in our chosen Interventional Medicine markets and create significant value for shareholders. In view of the above, it was perhaps surprising to see the SP down over 5% today.
Falling two weeks before results, hmmm interesting.
Quiet 'ere innit?
Not a fan. Btg is no great shakes either
Re: RNS Number : 9186E, BTG PLC, 21 July 2016: Louise and Rolf cash in another �900k+ worth of shares between them on 18th July. Nice. When are the BOD going to issue a dividend???
Share prices are forward indicators. BTG may be hedged but future hedges will be at 1.30 or possibly even lower. Is it £13M in earnings per 5c, do I recall? At 1.30; this stock must have a long way to run, albeit with earnings realization a little way down the track. Just dipping in with a further £30k.
AGM statement said wouldn't gain much from pound drop immediately as currency sold forward. Share price drop somewhat overdone IMO.
Thank you Jumbo. Much appreciated. Seems so silly when loads of buys at £1m are going through in the evenings! Best Wishes and thanks again.
Just one of those regular dramatic drops to let the lads top up maybe? NMan.
Can anyone tell me what is going on? Have I missed something? Many thanks
From BTGs annual report: “The average rate for the year was $1.51 compared to $1.61 in the prior year. A five cent movement in the dollar exchange rate results in an approximate £13m change in Group revenues.” With the current exchange rate at $1.32/£ BTG will benefit by around £50m pa!
SP seems to be holding up - in spite of Louise and Rolf's cashing out of a cool £3.3 million+ worth of shares between them recently, in part to cover tax and national insurance liabilities apparently. Lucky them.
If we are worried about Brexit -and I am - shares with strong earnings in dollars should do well. BTG has strong dollar earnings.
Strong broker backing here........ BTG broker views Date Broker Recommendation Price Old target price New target price Notes 18 May 16 Jefferies International Buy 619.75 850.00 840.00 Reiterates 18 May 16 JP Morgan Cazenove Neutral 619.75 780.00 800.00 Reiterates 18 May 16 Deutsche Bank Buy 619.75 755.00 740.00 Retains 17 May 16 Stifel Hold 619.75 - - Reiterates 17 May 16 Jefferies International Buy 619.75 850.00 850.00 Reiterates
30m: BTG after cracking results this morning being supported by brokers, BTG PLC BTG Deutsche Bank Buy 607.00 586.50 755.00 755.00 Reiterates
UPDATE 1 – BTG Group FY profit doubles, sees 8 – 15 pct rev growth 17-05-2016 09:34 (Adds forecast, analyst comment, share movement) May 17 (Reuters) – British healthcare group BTG Plc said its full-year pretax profit doubled from a year earlier as sales of its interventional therapies picked up, and forecast an 8-15 percent revenue growth for the next year. BTG shares rose as much as 2.4 percent to 600.50 pence on Tuesday morning. BTG said it expected revenue to be in the range 485 million pounds to 515 million pounds ($703.6 million-$746.7 million) for the financial year 2017 and costs related to research and development at about 85-95 million pounds. Jefferies analysts said the revenue forecast was as anticipated, but expected research and development expenses to go up from the company's forecast. Analysts on average were expecting 2017 revenue of 493.6 million pounds, according to Thomson Reuters I/B/E/S. The specialty drugmaker reported a pretax profit of 57.5 million pounds ($83.4 million) for the year ended March 31, up from 26.7 million pounds a year ago. ... BTG's revenue rose 22 percent to 447.5 million pounds, compared with 367.8 million pounds a year ago. The company's interventional therapies help treat blocked arteries and veins, and blocks blood supply to cancer-affected areas. BTG also makes specialty pharmaceutical products. Interventional therapies accounted for 33.6 percent of its revenue this year, only behind the revenue the company gets from licensing its products to other drugmakers. ($1 = 0.6897 pounds) (Reporting by Vidya L Nathan in Bengaluru, Editing by Sunil Nair) ((vidya.loganathan@thomsonreuters.com;; within U.S. +1 646 223 8780; outside U.S. +91 80 6749 6137;; Reuters Messaging: vidya.loganathan.thomsonreuters.com@reuters.net) Keywords: BTG GROUP RESULTS/